###begin article-title 0
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
Association of eNOS and HSP70 gene polymorphisms with glaucoma in Pakistani cohorts
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
To investigate the involvement of stress-regulating genes, endothelial nitric oxide synthase (eNOS) and heat shock protein 70 (HSP70) with primary open angle glaucoma (POAG) and primary closed angle glaucoma (PCAG).
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
POAG and PCAG patients recruited from different areas of Pakistan were diagnosed on the basis of clinical history, raised intraocular pressure (IOP), cup-to-disc ratio (CDR) and visual field defects. Their blood was collected and genomic DNA was extracted from it, followed by PCR amplification and VNTR typing of the eNOS gene, while the HSP70 SNP was analyzed with PCR-RFLP. For both of the polymorphisms, the genotype distribution of the POAG and PCAG patients was compared with unaffected controls.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 74 75 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 250 251 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 299 303 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 315 316 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 340 341 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 447 448 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 533 538 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS </italic>
###xml 626 627 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 702 703 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 774 780 762 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70 </italic>
###xml 869 870 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 944 945 928 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
HSP70 polymorphism was found to be significantly associated with PCAG (chi2=15.29 [p<0.001], OR=2.63 [95% CI=1.55-4.48]), with p<0.001 for the dominant model and OR=2.09 (95% CI=1.10-3.96) , with p<0.01 for the recessive model, but not with POAG (chi2=2.96 [p>0.05]). As opposed to this significant eNOS association, was seen with PCAG (chi2=6.33 [p<0.05], OR=2.09 [95% CI=1.12-3.89]), with p<0.01 for the dominant model, as well as with POAG (chi2=8.89 [p<0.05], OR=2.23 [95% CI=1.26-3.39]), with p<0.01 for dominant model. For the eNOS case, we found a significant association with the risk allele "a" for POAG patients (chi2=9.29 [p<0.01], OR=2.02 [95% CI=1.25-3.28, p=0.001]) and PCAG patients (chi2=7.59 [p<0.01], OR=1.99 [95% CI=1.18-3.37, p<0.01]). Similarly, in the HSP70 case, there was a significant association with the risk allele "C" for POAG patients (chi2=3.57 [p=0.05], OR=1.38 [95% CI=0.97-1.94, p<0.05]) and PCAG patients (chi2=18.32 (p<0.001), OR=2.16 [95% CI=1.49-3.13, p<0.001]).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
The intron 4 polymorphism of eNOS is associated with POAG, as well as PCAG, while the G+190C polymorphism in HSP70 is associated with PCAG, but not with POAG in the Pakistani population.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 921 922 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
Glaucoma is a multifactorial optic neuropathy characterized by apoptotic cell death of the retinal ganglion cells (RGCs) in the optic disc or retinal nerve fiber [1]. This irreversible retinal deterioration results in progressive visual field loss along with decreased contrast and color sensitivity [2]. Quigly et al. [3] have estimated that by the year 2010, approximately 60.5 million individuals will be affected by this disease, which causes bilateral blindness, and this number may rise to 79.6 million by the year 2020. Glaucoma is classified as a silent disease because patients usually do not have any signs and symptoms until the end stage, when considerable damage has been done to the eye [4, 5]. Increased intraocular pressure (IOP) is an established risk factor of the disease, along with old age, race and refractive error [6]. In addition to these factors, vascular [7], immunological [8] and neurotoxic [9] factors are also believed to cause glaucoma.
###end p 10
###begin p 11
###xml 14 16 14 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
Wiggs et al. [10] point to genetics as an additional risk factor for the disease. Different strategies used to understand the genetic risk factors have helped to define the molecular events responsible for some Mendelian forms of the disease. In addition, some of the chromosomal locations of the genes that are likely to be involved in common forms of glaucoma have also been identified.
###end p 11
###begin p 12
###xml 16 18 16 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 769 773 769 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 797 801 797 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 878 880 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 957 961 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 972 976 972 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 1057 1065 <span type="species:ncbi:9606">patients</span>
Galassi et al. [11] have shown that as a result of a variety of physiologic stresses, a highly conserved mechanism of gene regulation is activated. Stress or hypoxia in the tissues stimulates increased synthesis of Nitric oxide (NO), which results in an increased blood flow in the vessels of the tissue that helps to overcome the stress. Although several isoforms of nitric oxide synthase (NOS) have been reported in abundance in almost all layers of the retina, the circulating NO is synthesized solely in the vascular endothelium through the action of the endothelial nitric oxide synthase (eNOS) on the substrate L-arginine. Studies to identify the eNOS promoter element have revealed that many cis- and trans-acting factors together regulate the expression of the eNOS gene, and the level of eNOS expression, in turn, corresponds directly to the amount of NO in the blood [12]. Experiments have revealed that polymorphisms in the non-coding regions of eNOS may alter eNOS expression and thus cause a decrease in NO synthesis [13], which may predispose patients to hypertension, vasospasm and atherosclerosis.
###end p 12
###begin p 13
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 526 527 526 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 527 528 527 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 527 528 527 528 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>-</sup></bold>
###xml 563 564 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 563 564 563 564 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>-</sup></bold>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 848 852 848 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
In the vascular endothelium, an increase in the synthesis of NOS has been shown to be neuroprotective through the promotion of vasodilation and blood flow in the ocular tissue [11]. In contrast to previous models, which associated neuroprotection with higher eNOS activity, it has been observed that higher NO levels that correspond to an excess eNOS expression have pathological relevance and could be generally toxic. This pathogenicity model states that the excess NO freely diffuses to adjacent neurons and combines with O2- to form peroxynitrite anions (ONOO-), an extremely potent toxin which can set cell-death programs into motion, such as neuronal apoptosis [14]. An abundance of NOS has been found in the optic nerve head vessels of primary glaucoma patients, supporting the idea that the optic nerve damage in glaucoma can be related to eNOS overexpression [15].
###end p 13
###begin p 14
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 360 364 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
In determining the risk factors associated with increased eNOS expression, it has been recognized that beside the many environmental and other physiologic factors, there is also a significant genetic contribution. One of the genetic risk factors that has been identified is the 27-bp variable number of tandem repeat (VNTR) polymorphism present in intron 4 of eNOS, which is thought to alter NO production and contribute to vascular deregulation [16]. In addition, it has been shown that vascular deregulation and abnormal IOP in POAG might together be responsible for causing optic nerve damage, and both of these factors cause a reduction in ocular perfusion [11]. No study has been conducted to define the relationship of the vascular deregulation and PCAG.
###end p 14
###begin p 15
###xml 167 169 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 360 362 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 765 767 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 1026 1028 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 981 989 <span type="species:ncbi:9606">patients</span>
The mechanical stress resulting from elevated IOP, ischemia, excessive excitatory amino acids and excessive TNFalpha release increases stress in the optic nerve head [17]. Another mechanism elicited in response to stress is the recruitment of specific cellular proteins called "heat shock proteins" (HSPs), which have been shown to have a protective function [18], as the synthesis of the HSPs is upregulated in response to many forms of metabolic stress. These proteins are molecular chaperones that function in the proper refolding of the dysfunctional proteins and prevent protein aggregation, a mechanism that could be critical to the survival of RGCs; thus, a low expression of HSPs will abolish the defense mechanism against heat shock and stress in general [18]. Several investigators have shown that anti-HSP antibodies, through the induction of the apoptotic mechanism or the HSPs themselves via the stimulation of an immune response, may have pathogenic significance for patients with glaucomatous optic neuropathy [19].
###end p 15
###begin p 16
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
The present study was conducted to determine whether HSP70 and eNOS polymorphisms were associated with POAG and PCAG in the Pakistani population. We hope that our results will contribute toward a better understanding of the disease's causative agents.
###end p 16
###begin title 17
Methods
###end title 17
###begin p 18
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 142 154 <span type="species:ncbi:9606">participants</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
This was a multicenter case-control study in which the patients and controls were randomly selected from different hospitals in the area. The participants included 166 unaffected controls, 159 POAG patients and 111 PCAG patients.
###end p 18
###begin p 19
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients were selected on the basis of their clinical history, cup-to-disc ratio (CDR) evaluation, visual field evaluation and elevated IOP, and categorized into POAG and PCAG groups based on gonioscopic findings. In addition, to rule out any ocular anomaly, the controls also underwent applanation tonometery, slit lamp examination, CDR measurement and visual field assessment. Blood samples from all of the individuals were collected by venipuncture after informed written consent was obtained, and genomic DNA was extracted from these blood samples through a conventional phenol chloroform method [20]. This study has been approved by the Departmental Ethics Committee and conforms to all of the norms of the Helsinki Declaration.
###end p 19
###begin p 20
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 140 143 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 648 650 618 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2,</sub>
###xml 829 837 799 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
The 27-bp insertional VNTR in intron 4 of eNOS was typed with the use of PCR amplification. The VNTR region was amplified using the Gene amp(R) PCR system 2700 (ABI, Foster City, CA), with the help of the forward primer 5'-AGG CCC TAT GGT AGT GCC TTT-3' and the reverse primer 5'TCT CTT AGT GCT GTG CTC AC-3'. Briefly, the protocol consisted of 35 cycles of DNA denaturation at 95degreesC for 1 min, primer annealing at 60degreesC for 45 s and chain extension at 72degreesC for 1 min, followed by a final extension cycle at 72degreesC for 5 min. The constituents of the reaction consisted of: 1.2 microM of each primer, 10 mM of dNTPs, 2 mM of MgCl2, 1 U of Taq and 1x PCR buffer, along with 40-50 ng of DNA. The PCR products were electrophoresed on 4% agarose gels for 1 h and the bands were visualized under ultraviolet light (Figure 1). Two alleles were obtained when this region was amplified: "eNOS4a," which was 393 bp long and consisted of four 27-bp repeating units, and "eNOS4b," which was 420 bp long and consisted of five 27-bp repeating units.
###end p 20
###begin p 21
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOSb</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
Amplification product of the 27-bp insertional variable number of tandem repeat polymorphism in intron 4 of eNOS. The amplified products were separated by electrophoresis on 4% agarose gel. Lane L, 100-bp DNA ladder; lane NC, negative control (no template DNA); lane PC, positive control; lane 1, 2 and 5, homozygous eNOSb/b genotype (420 bp fragment); lane 3, heterozygous, eNOSa/b genotype (420-bp and 393-bp fragments); and lane 4, homozygous a/a genotype (393-bp fragment).
###end p 21
###begin p 22
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 497 498 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 915 923 883 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
A 488-bp fragment encompassing the HSP70 polymorphism () was PCR-amplified by using the forward and reverse primers, 5'-CGC CAT GGA GAC CAA CAC CC-3'and 5'-GCG GTT CCC TGC TCT CTG TC-3', respectively. Each of the 35 cycles consisted of a DNA denaturation step at 95degreesC for 1 min followed by primer annealing at 60degreesC for 45 s and chain extension at 72degreesC for 1 min. The concentration of both primers was 0.04 microM, and the reaction mixture also contained 0.2 mM dNTPs, 1.5 mM MgCl2, 1 U Taq, 1x PCR buffer, and approx 90-100 ng of DNA. The PCR-amplified products (17 microl) were then digested overnight with BrsB1, as recommended by the manufacturer (Fermentas, Burlington, Ontario). After digestion, the restriction enzyme was inactivated at 65degreesC for 20 min, and the digestion products were electrophoretically separated on 4% agarose gel for 2 h and visualized under UV transillumination (Figure 2). The wild-type G allele was recognized based on the presence of a single BrsB1 restriction enzyme recognition site that, after digestion, yielded a 461-bp and a 27-bp fragment, while the C allele that lacks the restriction site remained uncut.
###end p 22
###begin p 23
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
BrsB1 restriction enzyme-digested, PCR-amplified product of HSP70 G+190C polymorphism (). The digested products were separated by electrophoresis on 4% agarose gel. Lane L, 100-bp DNA ladder; lanes 1, 2 and 4, homozygous wild-type G allele (461 bp and 27 bp [not shown]); and lane 3 and 5, homozygous C risk allele (488 bp).
###end p 23
###begin p 24
###xml 126 127 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies in the unaffected controls and the patients (POAG and PCAG) were compared with the Pearson chi2 test. All of the data were analyzed by using SPSS (ver. 16; SPSS, Chicago, Il). The statistically significant differences were further analyzed using the statistical software Minitab (ver.15; Minitab, Chicago, Il). A p value of less than 0.05 was considered statistically significant.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 375 376 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 384 385 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 520 521 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 529 530 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 536 543 532 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 550 555 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 623 624 617 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 632 633 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 666 667 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 675 676 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 716 721 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 847 848 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 856 857 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 885 886 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 901 908 889 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 957 962 945 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 1042 1043 1028 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1051 1052 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 1109 1110 1093 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1161 1168 1145 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with POAG and PCAG and the controls were genotyped for the eNOS4a/b and HSP70 G+190C polymorphisms. In the controls, the frequencies of the eNOS4b/b, eNOS4b/a and eNOS4a/a were 83.7%, 12.7%, and 3.6%, respectively, whereas in the POAG group, these values were 70%, 24% and 6%, respectively, showing a significant association of the disease with the polymorphism (chi2=8.89, p<0.05). In the PCAG group, 71%, 22% and 7%, respectively, were also found to be significantly associated with the disease phenotype (chi2=6.33, p<0.05; Table 1). The eNOS4b/a genotype was found to be significantly associated with POAG (chi2=6.92 [p<0.01]), as well as with PCAG (chi2=3.93 [p<0.05]). As opposed to this finding, the eNOS4b/b genotype was found to be at a significantly higher frequency in the control samples when compared with the POAG group (chi2=8.87, p<0.01) or the PCAG group (chi2=6.26, p=0.01; Table 1). In addition to the genotype associations, the eNOS4a allele frequency was found to be significantly associated with both POAG ([chi2=9.29, p<0.01], OR=2.02 [95%CI=1.25-3.28, p=0.001]) and PCAG ([chi2=7.59, p<0.01], OR=1.99 [95%CI=1.18-3.37, p<0.01]; Table 1).
###end p 26
###begin title 27
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies of intron 4 polymorphism of eNOS in controls and patients.
###end title 27
###begin p 28
DM=dominant model, RM=recessive model
###end p 28
###begin p 29
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 425 432 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
The univariate logistic regression analysis revealed that the eNOS4a/b polymorphism was significantly associated with glaucoma (both POAG and PCAG), based on the dominant model of inheritance (for POAG, OR=2.23 [95% CI=1.26-3.39, p<0.01] and for PCAG, OR=2.09 [95% CI=1.12-3.89, p<0.01]), but not according to the recessive model (for POAG, OR=1.79 [95% CI=0.58-5.69, p>0.05] and for PCAG, OR=1.16 [95%CI=0.40-3.31, p>0.05]; Table 1).
###end p 29
###begin p 30
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 434 435 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 643 644 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 653 654 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 733 734 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 772 773 764 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 781 782 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</italic>
###xml 1032 1033 1022 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1104 1105 1092 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1114 1115 1102 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 1150 1151 1138 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
###xml 1159 1166 1147 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 920 927 <span type="species:ncbi:9606">patient</span>
To study the association of HSP70 polymorphism G+190C with glaucoma, the POAG and PCAG patients, as well as the control samples, were genotyped. In the control group, the frequency of GG, GC and CC genotypes was 58%, 27% and 15%, respectively. For POAG patients, this distribution was 48%, 32% and 20%, respectively, with no significant association found for the genotype distribution in the patients, as compared to the controls (chi2=2.96, p>0.05). In PCAG patients, the frequency of the GG, GC and CC genotypes were 34%, 39% and 27%, respectively, and the genotype distribution was found to be significantly associated with the disease (chi2=15.29, p<0.001). The genotype CC was found to be significantly associated with PCAG (chi2=5.26, p=0.01), but not with POAG (chi2=1.12, p>0.05). In addition to the genotype distribution, the frequency of the G allele was found to be at a significantly lower frequency in both patient groups compared to in the control group, whereas the frequency of the C allele was high in the POAG (chi2=3.57, p=0.05, OR=1.38 [95% CI=0.97-1.94, p<0.05]) and PCAG groups (chi2=18.32, p<0.001, OR=2.16 [95% CI=1.49-3.13, p<0.001]; Table 2).
###end p 30
###begin title 31
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies of G+190C polymorphism of HSP70 in controls and patients.
###end title 31
###begin p 32
DM=dominant model, RM=recessive model
###end p 32
###begin p 33
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</italic>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</italic>
Univariate analysis of the HSP70 G+190C polymorphism revealed that the polymorphism was not associated with POAG when the data was analyzed according to a dominant model (OR=1.44 [95% CI=0.91-2.29, p>0.05]) or a recessive model (OR=1.37 [95% CI=0.74-2.54, p>0.05]). However, an analysis of PCAG revealed the data to be significantly associated based on both the dominant (OR=2.63 [95% CI=1.55-4.48, p<0.001]) and recessive models (OR=2.09 [95% CI=1.10-3.96, p<0.01]).
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
Glaucoma is a disease leading to optic neuropathy and the second leading cause of blindness in the world. The slow, progressive loss of the retinal nerve ganglion cells in glaucoma results in peripheral vision loss. Glaucoma is a multifactorial disease and its exact etiology is still unknown. It has been reported that both genetic and environmental factors are significant in the progression of the disease. A multitude of recent genetic linkage studies have led to the identification of genetic loci, while genome wide search techniques have been used to identify single nucleotide polymorphisms, which have been observed to be associated with the disease.
###end p 35
###begin p 36
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
In the present study, we provide data on two different polymorphisms of two genes, the 27-bp repeat eNOS VNTR polymorphism and the HSP70 G+190C polymorphism. The eNOS and HSP70 genes have been shown to elicit enhanced transcription levels of the respective mRNA when the body is under stress [18,21].
###end p 36
###begin p 37
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
eNOS is involved in different processes, like neurotransmission, the regulation of vascular tone, vasodilatation and apoptosis. In addition, it also regulates blood flow to the ocular tissues and has been implicated in the pathogenesis of cardiovascular diseases and different neurodegenerative disorders, like diabetic retinopathy [22], glaucoma [23] and migraines [24]. In focusing on glaucoma, Liu and Neufeld [21] demonstrated that RGC degeneration in the glaucomatous optic nerve head of POAG patients clearly corresponds to excess plasma NO-mediated neurotoxicity. However, the authors did not conduct any genetic studies to find the susceptible loci.
###end p 37
###begin p 38
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 530 534 530 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
Plasma NO levels are regulated by eNOS, thus any environmental or genetic risk factor that enhances eNOS expression would contribute to NO mediated toxicity. It has been established that the VNTR in the intron 4 of eNOS significantly influences the plasma NO levels. Functional studies have shown that the variant a allele (with four 27-bp repeats) in homozygous form is strongly correlated with increased plasma NO levels, which were twice as high as the level found in the b/b genotype (with five 27-bp repeats), indicating the eNOS' underlying potential for excess NO-related pathogenicity [25].
###end p 38
###begin p 39
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 479 483 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1027 1031 1027 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1137 1141 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1263 1267 1263 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
It was hypothesized that the molecular mechanism of eNOS expression was regulated at the transcriptional levels by microRNAs, which can be derived from the intron during pre-mRNA splicing [26]. Based on this hypothesis, Zhang et al. [27] conducted experiments and established the role of intron 4 VNTR repeat with eNOS expression by identifying a 27-nucleotide microRNA sequence derived from the 27-nucleotide repeat within intron 4 of eNOS. This microRNA was shown to represses eNOS expression by interfering with the gene transcription efficiency. In addition, they demonstrated that this microRNA acted as an endogenous sequence-specific feedback regulatory molecule that reversibly inhibited this process and thus enabled the rapid turnover of eNOS molecules to minimize the damage associated with stress and hypoxia. The presence of the endogenous expression of the microRNA from intronic sequences was further demonstrated by the unexpected finding that the 5' and 3' ends of the 27-nucleotide repeat unit in intron 4 of eNOS had splice donor and acceptor sites (AG and GA) similar to the 5' and 3' bases at the exonic ends in the eNOS genomic sequence. This further supported the hypothesis that the intact microRNAs are produced when pre-mRNA splicing of eNOS occurs and that the amount of microRNA is determined by the number of repeats in intron 4 [27].
###end p 39
###begin p 40
###xml 13 15 13 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 626 631 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 984 992 <span type="species:ncbi:9606">patients</span>
Zang et al. [27] also postulated that the amount of microRNA would vary from individual to individual, depending on the number of repeats at this position, which would account for the variations observed between the individuals and their expression of eNOS and its association with cardiovascular risk. Consequently, compared to the b allele with five 27-bp repeats, variant a allele with 4 repeats produced fewer microRNAs and hence, reduced transcriptional repression would occur, correlating with the increased plasma NO. Our current results are in line with the above results, as we found a significant association of the eNOS4 a/b genotype with both forms of glaucoma in the Pakistani groups, which is probably a result of high plasma NO levels that are toxic to the optic nerve and ultimately cause its degeneration, a classic hallmark of glaucoma. Earlier studies conducted to establish a possible association between glaucoma and altered NOS expression focused mainly on POAG patients [11,12] and were able to show a positive correlation between this polymorphism and the disease, matching our results.
###end p 40
###begin p 41
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS4</italic>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
In the current work, we also studied PCAG as an impairment in the ocular blood flow that might lead to closure of the angle, which can be partially associated with altered eNOS expression and the resultant NO-mediated neurotoxicity. Our results indicate that there is indeed a correlation between PCAG and the polymorphism in the eNOS gene, as we found a significantly higher frequency of the variant eNOS4a allele in PCAG patients compared to the controls. Thus, in the Pakistani PCAG and POAG groups, the disease could be associated with increased NOS activity.
###end p 41
###begin p 42
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 642 646 642 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 1120 1122 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 679 687 <span type="species:ncbi:9606">patients</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
###xml 852 860 <span type="species:ncbi:9606">patients</span>
###xml 970 978 <span type="species:ncbi:9606">patients</span>
Our findings are consistent with the results of Sakai et al. [28], who found the T(-786)C polymorphism of eNOS to be a risk factor in patients developing non-arteritic anterior ischemic optic neuropathy (NAION) disease [28]. However, while studying glaucoma, Logan et al. [13] were unable to show a significant association between eNOS polymorphism T786C and VNTR repeat polymorphism and the disease. Similarly, Sena et al. [29] and Lin et al. [30] did not find any association between POAG and eNOS intron 4 VNTR. As opposed to this finding, however, Colombo et al. [31] have shown an association between Glu289Asp and T788C polymorphism of eNOS and cardiac myopathies, wherein patients who carried both polymorphisms had a higher risk of developing the disease. Polak et al. [32] studied the role of the NO system in glaucoma patients by giving POAG patients and normal healthy controls NG-monomethyl-L-arginine, which is an NOS inhibitor. They observed that glaucoma patients did not respond to the drug due to abnormal NOS activity, whereas healthy controls showed reduced choroidal and optic nerve head blood flow [32].
###end p 42
###begin p 43
###xml 585 592 <span type="species:ncbi:9606">patient</span>
###xml 757 764 <span type="species:ncbi:9606">patient</span>
###xml 782 790 <span type="species:ncbi:9606">patients</span>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
NO is responsible for maintaining arteries' vasodilation, which keeps the ocular blood flow constant. When the endothelial function is deregulated, the blood supply to the tissue is altered and impaired blood flow damages the optic nerve and leads to the development of glaucomatous changes in the optic nerve, which then results in an increase in the CDR. In our study group, an increased CDR, as compared to the controls (C/D=0.29+/-0.11), was observed in the POAG group (C/D=0.75+/-0.24, p<0.001), as well as in the PCAG group (C/D=0.67+/-0.28, p<0.001). This increased CDR in both patient groups is evidence of excessive optic nerve damage, possibly as a result of NO activity. In addition to the differences in the CDR between the controls and the two patient groups, the POAG patients had a significantly higher CDR compared to the PCAG patients (p<0.001).
###end p 43
###begin p 44
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
It has been suggested that the HSPs are involved in the defense mechanism of stress-mediated neuron injury, caused by an increased IOP in glaucoma patients. In addition, these proteins recruit antigen presenting cells, thus they also act as immune stimulatory molecules. Therefore, in addition to their neuroprotective function, when they are overexpressed in the cell, they potentially contribute to disease progression by activating the autostimulatory response that leads to optic nerve neuropathy [17,18]. This is supported by the observation that in glaucoma patients, increased titers of anti-HSP antibodies are present, which facilitate the disease's progression by diminishing the protective abilities of the native HSPs [33].
###end p 44
###begin p 45
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 893 898 893 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
This tight regulation of the HSPs' expression pattern determines the fate of the cell, where underexpression leads to an inefficient stress response and overexpression drives the immunodestruction, with the outcome in both cases being destruction -- driven by the oxidative free radicals in one case and by cytokines in the other, respectively. This is supported by a study conducted by Tezel et al. [33], who have previously shown HSPs to be significant enhancers of both the cytoprotective and neurodegenerative functions of the immune system in RGCs and glial cells, and clearly demonstrated that these proteins were critical in facilitating the glaucomatous changes caused by optic nerve damage and neurodegeneration [33]. Because optic nerve neuropathy in glaucoma is the major cause of blindness in Pakistan, we were therefore interested in studying the possible association between the HSP70 polymorphism and POAG and PCAG in the Pakistani population.
###end p 45
###begin p 46
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 443 448 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 692 699 692 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70&#8211;1</italic>
###xml 786 791 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
Our specific interest was to study the stress-mediated responses and their association with glaucoma. We thus chose the G+190C polymorphism for genotypic studies, as this polymorphism has previously been shown to be associated with reduced HSP70 expression, which could represent an inability to cope with cellular stress and perform cytoprotective functions. Functional analyses of the G+190C polymorphism, which maps to the 5' UTR region of HSP70, have revealed that compared with the G allele, the variant C allele causes reduced promoter activity and lower HSP70 protein levels [34]. Tosaka et al. [19] had previously reported a significant association between the A-110C polymorphism of HSP70-1 and POAG (p=0.026) in the Japanese population; this polymorphism is known to increase HSP70 expression, thus supporting the hypothesis that neuropathy is associated with autoimmunity. However, Tosaka et al. [19] did not find any association between glaucoma and the G+190C polymorphism, which supports the alternate model of pathogenicity related to HSP70 cytoprotective functions. As in the Japanese population, we also did not observe any association between the G+190C polymorphism and POAG, but we did find a highly significant association between the polymorphism and PCAG in the Pakistani study group.
###end p 46
###begin p 47
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS</italic>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP70</italic>
###xml 719 723 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
One possible manner in which eNOS and HSPs might contribute to PCAG is by affecting the expression of matrix metalloproteinases (MMPs). MMPs have been found to be involved in the regulation of IOP and might play a significant role in the normal and pathogenic functions of the eye [35]. The malfunction of the MMP9 protein has previously been shown to be associated with PCAG [36]. The NOS gene plays an important role in controlling the activity of MMPs in flow-induced remodeling [37] and hence, the polymorphism we studied could potentially be associated with the overactivation of MMPs, which could then possibly result in PCAG. Other lines of evidence have also suggested a role for HSP70 in the expression of the MMP9 gene [38]. It must be pointed out that to fully understand the role of HSPs in the regulation of MMPs, it is important to conduct further expression and activity assays.
###end p 47
###begin p 48
###xml 437 445 <span type="species:ncbi:9606">patients</span>
In conclusion, glaucoma is a heterogeneous disorder with different environmental and genetic factors driving the etiology of the disease. Various polymorphisms have been reported to be associated with this disease in different populations. Our study represents a step forward in terms of clarifying the role of the stress-related cellular components eNOS and HSP70 and their role in causing glaucoma, particularly in regard to Pakistani patients, and in terms of contributing to the current body of knowledge. There is a further need to conduct studies in different populations across the world to fully unravel the genetic basis of glaucoma, which will ultimately lead to a better understanding of the disease's underlying mechanisms. Once the disease's mechanisms are completely understood, better therapeutic interventions can be devised.
###end p 48
###begin title 49
Acknowledgments
###end title 49
###begin p 50
The authors wish to thank all the study subjects for donating their blood samples. The authors would like to acknowledge Mr. Joseph Lal and his staff at the Taxila Eye Hospital for their help in the study.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
Current management of glaucoma and the need for complete therapy.
###end article-title 52
###begin article-title 53
Oxygen and blood flow: players in the pathogenesis of glaucoma.
###end article-title 53
###begin article-title 54
###xml 14 20 <span type="species:ncbi:9606">people</span>
The number of people with glaucoma worldwide in 2010 and 2020.
###end article-title 54
###begin article-title 55
Glaucoma.
###end article-title 55
###begin article-title 56
Prevalence and distribution of glaucoma in central India (Glaucoma Survey 2001).
###end article-title 56
###begin article-title 57
Risk factors for progression to blindness in high tension primary open angle glaucoma: Comparison of blind and nonblind subjects.
###end article-title 57
###begin article-title 58
(Osservatorio sulla Patologia glaucomatosa, Indagine Medico Epidemiologica); CONPROSO (Collegio Nazionale dei Professori Ordinari di Scienze Oftalmologiche). Vascular risk factors in glaucoma: the results of a national survey.
###end article-title 58
###begin article-title 59
Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent.
###end article-title 59
###begin article-title 60
Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.
###end article-title 60
###begin article-title 61
Genetic etiologies of glaucoma.
###end article-title 61
###begin article-title 62
Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma.
###end article-title 62
###begin article-title 63
###xml 110 115 <span type="species:ncbi:9606">Human</span>
Lai, Kulkarni G, D'Abreo C, Wong GK, Miller TL, Chan Y, Atkins J, Wang Y, Marsden PA. Characterization of the Human Endothelial Nitric-oxide Synthase Promoter.
###end article-title 63
###begin article-title 64
Evidence for association of endothelial nitric oxide synthase gene in subjects with glaucoma and a history of migraine.
###end article-title 64
###begin article-title 65
A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds.
###end article-title 65
###begin article-title 66
###xml 29 34 <span type="species:ncbi:9606">human</span>
Nitric oxide synthase in the human glaucomatous optic nerve head.
###end article-title 66
###begin article-title 67
The 27-bp repeat polymorphism in intron 4 (27 bp-VNTR) of endothelial nitric oxide synthase (eNOS) gene is associated with albumin to creatinine ratio in Mexican Americans.
###end article-title 67
###begin article-title 68
Heat shock proteins, immunity and glaucoma.
###end article-title 68
###begin article-title 69
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer in a rat glaucoma model.
###end article-title 69
###begin article-title 70
Association between open-angle glaucoma and gene polymorphism for heat-shock protein 70-1.
###end article-title 70
###begin article-title 71
###xml 95 100 <span type="species:ncbi:9606">human</span>
Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy.
###end article-title 71
###begin article-title 72
Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes.
###end article-title 72
###begin article-title 73
Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy.
###end article-title 73
###begin article-title 74
Increased nitric oxide stress is associated with migraine.
###end article-title 74
###begin article-title 75
Modulation by pathophysiological stimuli of the shear stress-induced up-regulation of endothelial nitric oxide synthase expression in endothelial cells.
###end article-title 75
###begin article-title 76
eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues.
###end article-title 76
###begin article-title 77
Regulation of endothelial nitric oxide synthase by small RNA.
###end article-title 77
###begin article-title 78
Endothelial nitric oxide synthase gene polymorphisms in non-arteritic anterior ischemic optic neuropathy.
###end article-title 78
###begin article-title 79
Distribution of Oxidation Enzyme eNOS and myeloperoxidase in primary open angle glaucoma.
###end article-title 79
###begin article-title 80
Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease.
###end article-title 80
###begin article-title 81
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Altered nitric oxide system in patients with open-angle glaucoma.
###end article-title 81
###begin article-title 82
Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes.
###end article-title 82
###begin article-title 83
Functional SNPs in HSPA1A gene predict risk of coronary heart disease.
###end article-title 83
###begin article-title 84
New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology.
###end article-title 84
###begin article-title 85
###xml 143 151 <span type="species:ncbi:9606">patients</span>
The association of single nucleotide polymorphisms in the MMP-9 genes with susceptibility to acute primary angle closure glaucoma in Taiwanese patients
###end article-title 85
###begin article-title 86
###xml 97 100 <span type="species:ncbi:10116">rat</span>
Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries.
###end article-title 86
###begin article-title 87
###xml 124 129 <span type="species:ncbi:9606">human</span>
Release of heat shock protein 70 (Hsp70) and the effects of extracellular Hsp70 on matric metalloproteinase-9 expression in human monocytic U937 cells.
###end article-title 87

